225Ac-PSMA is one of the novel theragnostic alpha endoradiotherapy agents under investigation for salvage therapy in metastatic castration resistant prostate cancer (mCRPC). We present a case of hormone naïve patient with high-volume metastatic, symptomatic prostate cancer involving the lungs. The ...